GLP-1 & compounded medication availability in Alabama (2026)
Alabama has built one of the most detailed state files in this entire family: a 2024 ruling on how GLP-1 compounding must source its ingredients, a 2026 official notice on research-grade peptides, and a consumer-protection lawsuit that ended with a clinic permanently closed. The GLP-1 lines still ship here, inside the exact lane the state drew, while four peptide rows sit at No pending a compliance answer we refuse to guess. Everything consequential below is cited to Alabama’s own documents.
Ten lines, the Alabama answers
| Product line | Available in Alabama? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Patient-specific prescriptions; pharmaceutical-grade base ingredient from permitted suppliers, per the cited 2024 ruling. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same sourcing-and-permit lane as the semaglutide row. |
| NAD+ | Yes | 8–10 business days | Not a peptide; outside the 2026 notice. Ships normally. |
| Sermorelin | No | N/A | Paused for Alabama pending review of the 2026 peptide notice’s reach. A compliance call, not a copy change. |
| Glutathione | No | N/A | Not in our formulary in any state. |
| BPC-157 | No | N/A | Carried elsewhere; paused for Alabama while the 2026 notice’s reach is reviewed. Cited below. |
| TB-500 | No | N/A | Same pause, same cited notice, same pending review. |
| KPV | No | N/A | Not carried in any state, and inside the notice’s subject matter besides. |
| Epitalon | No | N/A | Paused for Alabama on the same conservative basis as its siblings. |
| MOTS-c | No | N/A | Paused here too. Its federal record differs, but the Alabama question is the same. |
Six No rows, and four of them are deliberate pauses rather than settled answers. We publish the pause instead of the guess; when the review lands, the feed moves and this table moves with it. Reviewed November 16, 2026.
The research-peptide pause in Alabama, explained
In most states OrderlyMeds dispenses BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables and carries KPV nowhere. Alabama is different, and the difference is one document.
The Alabama Board of Medical Examiners has issued an official notice stating that under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA-approved or research-grade peptide; that no CRNP, CNM, or PA is legally authorized to prescribe, administer, advise, or dispense one; that consent forms describing a product as research-grade do not mitigate the provider’s professional or legal liability; and that physicians must purchase all prescription products and ingredients from entities permitted by the state’s pharmacy board. Source: Alabama Board of Medical Examiners — official notice on research-grade peptides.
Whether that notice reaches a pharmacy-compounded, pharmaceutical-grade peptide dispensed under HHS’s October 2026 federal policy, or only the research-grade vials it describes, is a genuine open question. We have handed it to compliance review instead of answering it in our own favor, so all five rows read No for Alabama today. Each line’s federal record follows anyway, because it is true in every state and because an honest No deserves the same documentation as a Yes.
BPC-157 for Alabama
Paused. Not dispensed into Alabama while the notice cited above is under review. The federal record that travels with this line everywhere:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 for Alabama
Also paused for Alabama on the same basis. Its own federal facts:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV for Alabama
A No twice over: OrderlyMeds compounds its peptide lines as injectables only, which excludes KPV in every state, and Alabama’s notice covers this territory independently.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon for Alabama
Paused for Alabama pending the same review. Its record:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c for Alabama
Paused here as well. Its federal paper trail is notably its own, set out below, but the Alabama pause applies to it all the same.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Alabama’s medical and pharmacy regulators say about compounded medications
Alabama’s file runs through its medical board as much as its pharmacy board, and it is unusually concrete: a ruling, an advisory, a notice, and a lawsuit. In order:
In a declaratory ruling issued August 8, 2024 on a petition from the state’s pharmacy board, the Alabama Board of Medical Examiners held that Alabama-licensed physicians are not permitted to compound or dispense a drug using non-prescription-quality ingredients, are required to purchase prescription products and ingredients only from entities permitted by the Alabama State Board of Pharmacy, and must comply with USP standards when compounding GLP-1 products. Source: ALBME declaratory ruling (PDF).
A September 2023 ALBME advisory had already stated that the use of semaglutide salts, or of any non-pharmaceutical-grade active pharmaceutical ingredient not produced by an FDA-registered establishment, is prohibited in compounding. Source: ALBME — Concerns with Semaglutide and Other GLP-1 Receptor Agonists (PDF).
The state’s pharmacy board, in its own newsletter, requires pharmacists to purchase and use only prescription-quality active pharmaceutical ingredients when compounding for human use, and requires any outlet selling GLP-1 powder or products to Alabama practitioners to hold the appropriate board permit; the ruling above likewise quotes Ala. Code §34-23-32(g), under which no supply-chain entity may ship a legend drug into the state without a valid board-issued permit. Sources: Alabama Board of Pharmacy newsletter, August 2024 (NABP-hosted PDF) · ALBME ruling quoting §34-23-32(g).
Alabama permits telehealth prescribing of legend drugs without a prior in-person visit; the in-person-encounter requirement attaches to controlled substances, and a physician who provides telehealth to the same patient for the same unresolved condition more than four times in 12 months must see the patient in person or refer them. Sources: ALBME telemedicine guidance · CCHP Policy Finder — Alabama.
Enforcement is real here: in November 2025 the Alabama Attorney General sued a Cullman IV clinic for administering research-grade tirzepatide and semaglutide marketed as pharmaceutical-grade, and the January 2026 settlement closed the business permanently, with restitution, penalties, and a surrendered nursing license. Sources: Alabama Attorney General — suit announcement · Alabama Attorney General — settlement announcement.
Read as one file, Alabama’s message is about ingredients and supply chains: pharmaceutical-grade material, permitted suppliers, real pharmacies. That is a lane an OrderlyMeds GLP-1 order already drives in: patient-specific prescription, permitted pharmacy, base-form ingredient with its paperwork. That is why those two rows stay Yes while the peptide rows wait for a considered answer instead of a convenient one.
Alabama availability FAQs
Is compounded semaglutide available in Alabama?
Yes. OrderlyMeds ships compounded semaglutide to Alabama addresses under patient-specific prescriptions, from permitted pharmacies using pharmaceutical-grade base ingredient, which is the exact lane Alabama’s cited 2024 ruling draws. New customers start at $74/month for the first two months.
Can I get BPC-157, TB-500, Epitalon or MOTS-c shipped to Alabama?
Not right now. Alabama’s medical board has issued an official notice on non-FDA-approved research-grade peptides, and whether it reaches pharmacy-compounded peptides dispensed under the 2026 federal policy is a question we have handed to compliance review rather than answered in our own favor. Those four rows show No until that review lands.
What does ship to Alabama today?
Compounded semaglutide, compounded tirzepatide, and NAD+, each under a patient-specific prescription from a pharmacy permitted for Alabama, in 8–10 business days.
Does Alabama limit how often I can use telehealth?
There is one rule worth knowing: after four telehealth visits in 12 months for the same unresolved condition, Alabama expects an in-person visit or a referral. The regulator section above cites the medical board’s own page.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
